Pharming Group Liabilities 2024

Pharming Group Aktienanalyse

What does Pharming Group do?

Pharming Group NV was founded in 1988 and is headquartered in the Netherlands. The company specializes in the development and marketing of medical products for the treatment of rare diseases. Its business model is based on the discovery and development of recombinant proteins. These proteins are produced using genetic engineering techniques and serve as the foundation for the development of therapeutic products in various areas. The main focus of Pharming Group NV is the manufacturing and marketing of biopharmaceuticals. The company has a wide range of products used in the treatment of rare diseases, including C1-esterase inhibitor preparations used for acute attacks in hereditary angioedema. Another important product of Pharming Group NV is recombinant human lysozyme. It is used in the treatment of cystic fibrosis and has shown promising results as a therapeutic approach. Pharming Group NV also collaborates closely with various research and development organizations to develop new products and expand knowledge in the medical industry. The company has experienced impressive growth in recent years. In 2019, Pharming Group NV achieved a revenue of 149 million euros. A significant portion of this revenue was generated through the sale of C1-esterase inhibitor preparations. Pharming Group NV has also made a name for itself in the international market. The company has branches in the USA and Europe and works closely with international regulatory authorities to ensure smooth approval and marketing of its products. Overall, Pharming Group NV has a promising future as it continues to invest in research, development, and expansion of its product portfolio. By focusing on the development of products for the treatment of rare diseases, Pharming Group NV positions itself as a leading company in the medical industry and contributes to improving the lives of people worldwide. Pharming Group ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Liabilities Details

Assessing Pharming Group's Liabilities

Pharming Group's liabilities constitute the company's financial obligations and debts owed to external parties and stakeholders. They are categorized into current liabilities, due within a year, and long-term liabilities, which are due over a longer period. A detailed assessment of these liabilities is crucial for evaluating Pharming Group's financial stability, operational efficiency, and long-term viability.

Year-to-Year Comparison

By comparing Pharming Group's liabilities year-over-year, investors can identify trends, shifts, and anomalies in the company’s financial positioning. A decrease in total liabilities often signals financial strengthening, while an increase might indicate enhanced investments, acquisitions, or potential financial strain.

Impact on Investments

Pharming Group's total liabilities play a significant role in determining the company's leverage and risk profile. Investors and analysts examine this aspect meticulously to ascertain the firm’s ability to meet its financial obligations, which influences investment attractiveness and credit ratings.

Interpreting Liability Fluctuations

Shifts in Pharming Group’s liability structure indicate changes in its financial management and strategy. A reduction in liabilities reflects efficient financial management or debt payoffs, while an increase may suggest expansion, acquisition activities, or accruing operational expenses, each carrying distinct implications for investors.

Frequently Asked Questions about Pharming Group stock

What is the level of liabilities of Pharming Group this year?

Pharming Group has a debt balance of 244.07 M USD this year.

What were the liabilities of Pharming Group compared to the previous year?

The liabilities of Pharming Group have increased by 10.36% increased compared to the previous year.

What are the consequences of high debt for investors of Pharming Group?

High liabilities can pose a risk for investors of Pharming Group, as they can weaken the company's financial position and impair its ability to meet its obligations.

What consequences do low liabilities have for investors in Pharming Group?

Low liabilities mean that Pharming Group has a strong financial position and is able to meet its obligations without overburdening its finances.

How does an increase in liabilities of Pharming Group affect the company?

An increase in liabilities of Pharming Group can lead to the company having more obligations and potentially find it more difficult to meet its financial commitments.

How does a reduction in the liabilities of Pharming Group affect the company?

A decrease in the liabilities of Pharming Group can lead to the company having fewer obligations and a stronger financial position, which can make it easier for the company to fulfill its financial commitments.

What are some factors that influence the liabilities of Pharming Group?

Some factors that can influence the liabilities of Pharming Group include investments, acquisitions, operating costs, and sales development.

Why is the level of liabilities of Pharming Group so important for investors?

The liabilities of Pharming Group are important for investors as they serve as an indicator of the company's financial stability and provide investors with information on how the company meets its financial obligations.

What strategic measures can Pharming Group take to modify the liabilities?

To change its liabilities, Pharming Group can take measures such as cost savings, increasing revenue, selling assets, raising investments, or forming partnerships. It is important for the company to conduct a thorough review of its financial situation to choose the best strategic actions.

How much dividend does Pharming Group pay?

Over the past 12 months, Pharming Group paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Pharming Group is expected to pay a dividend of 0 USD.

What is the dividend yield of Pharming Group?

The current dividend yield of Pharming Group is .

When does Pharming Group pay dividends?

Pharming Group pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Pharming Group?

Pharming Group paid dividends every year for the past 0 years.

What is the dividend of Pharming Group?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Pharming Group located?

Pharming Group is assigned to the 'Health' sector.

Wann musste ich die Aktien von Pharming Group kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Pharming Group from 12/18/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 12/18/2024.

When did Pharming Group pay the last dividend?

The last dividend was paid out on 12/18/2024.

What was the dividend of Pharming Group in the year 2023?

In the year 2023, Pharming Group distributed 0 USD as dividends.

In which currency does Pharming Group pay out the dividend?

The dividends of Pharming Group are distributed in USD.